Actively Recruiting
IMMunological resPonse Assessment afteR Acute iSchemic Stroke Treated With Endovascular Therapy (IMPRESS)
Led by Fondation Ophtalmologique Adolphe de Rothschild · Updated on 2026-01-23
1200
Participants Needed
1
Research Sites
273 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
IMPRESS study aims to describe the immuno-inflammatory and thrombo-inflammatory profiles during the first 24/36 hours of treatment of patients suffering from AIC treated with TM, and to study the possible impact of these profiles on the functional prognosis at 3 and 12 months of AIC treatment.
CONDITIONS
Official Title
IMMunological resPonse Assessment afteR Acute iSchemic Stroke Treated With Endovascular Therapy (IMPRESS)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient with an acute ischemic stroke planned for or treated by mechanical thrombectomy
- Provided informed consent or consent from a trusted person if patient unable
- Affiliated with or beneficiary of a social security or equivalent scheme
You will not qualify if you...
- Pregnant or breastfeeding women
- Patients under legal protection measures such as guardianship or conservatorship
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hôpital Fondation Adolphe de Rothschild
Paris, Paris, France, 75019
Actively Recruiting
Research Team
B
Benjamin Maier, MD
CONTACT
A
Amélie Yavchitz, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here